Simona Sacco Selected Research

erenumab

6/2022	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
3/2022	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
1/2022	Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.
1/2022	Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index.
8/2021	Early outcomes of migraine after erenumab discontinuation: data from a real-life setting.
3/2021	Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series.
1/2021	Association between response to triptans and response to erenumab: real-life data.
1/2021	Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab.
8/2020	Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
4/2020	Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simona Sacco Research Topics

Disease

49	Migraine Disorders (Migraine) 06/2022 - 08/2008
28	Stroke (Strokes) 08/2022 - 01/2009
20	Headache (Headaches) 06/2022 - 07/2012
19	Ischemic Stroke 06/2022 - 01/2005
9	Hemorrhage 08/2022 - 04/2015
9	Atrial Fibrillation 01/2022 - 08/2015
8	Pain (Aches) 08/2021 - 11/2004
5	Cerebral Hemorrhage 10/2021 - 07/2012
3	Secondary Headache Disorders 01/2022 - 05/2019
3	Prescription Drug Overuse 04/2020 - 09/2018
3	Migraine with Aura (Familial Hemiplegic Migraine) 10/2017 - 04/2012
3	Hypertension (High Blood Pressure) 09/2014 - 08/2008
2	Infarction (Infarctions) 08/2022 - 08/2022
2	Disease Progression 08/2020 - 03/2019
2	Embolic Stroke 01/2019 - 08/2015
2	Consciousness Disorders 01/2016 - 01/2015
1	Hemianopsia (Bitemporal Hemianopsia) 08/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/2021
1	Patent Foramen Ovale 01/2021
1	Post-Traumatic Headache 01/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 01/2021
1	Neoplasms (Cancer) 12/2020
1	Liver Diseases (Liver Disease) 12/2020
1	Bacterial Endocarditis 12/2020
1	Cluster Headache (Cluster Headaches) 11/2020
1	Weight Loss (Weight Reduction) 02/2020
1	Overweight 02/2020
1	Myasthenia Gravis 01/2020
1	Disease Susceptibility (Diathesis) 03/2019
1	Leukoaraiosis 01/2019
1	Brain Injuries (Brain Injury) 01/2018

Drug/Important Bio-Agent (IBA)

13	erenumabIBA 06/2022 - 01/2019
13	Monoclonal AntibodiesIBA 06/2022 - 01/2019
13	Calcitonin Gene-Related PeptideIBA 06/2022 - 01/2019
12	AnticoagulantsIBA 01/2022 - 02/2015
7	Type A Botulinum Toxins (Botox)FDA Link 12/2021 - 09/2018
5	Estrogens (Estrogen)FDA Link 01/2022 - 01/2015
5	Tryptamines (Triptans)IBA 05/2021 - 01/2020
4	Hormones (Hormone)IBA 01/2022 - 04/2012
4	Pharmaceutical PreparationsIBA 01/2022 - 04/2016
4	Vitamin K FDA Link 01/2021 - 11/2017
4	Biomarkers (Surrogate Marker)IBA 08/2020 - 04/2016
4	Contraceptive Agents (Contraceptives)IBA 01/2020 - 04/2012
4	sirioIBA 07/2013 - 01/2009
3	galcanezumabIBA 06/2022 - 01/2019
3	fremanezumabIBA 06/2022 - 01/2019
3	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2022 - 10/2019
2	ORALIT (ORS)IBA 08/2022 - 12/2020
2	eptinezumabIBA 06/2022 - 01/2019
2	salicylhydroxamic acid (SHAM)IBA 01/2022 - 11/2021
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 01/2020
2	LipidsIBA 04/2016 - 02/2015
2	Baclofen FDA LinkGeneric 01/2015 - 01/2007
2	Antihypertensive Agents (Antihypertensives)IBA 07/2011 - 08/2008
1	Glucose (Dextrose)FDA LinkGeneric 08/2022
1	mesoglycanIBA 08/2022
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2022
1	VaccinesIBA 01/2022
1	Tenecteplase FDA Link 01/2022
1	Analgesics (Analgesic Drugs)IBA 05/2021
1	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Clopidogrel (Plavix)FDA Link 01/2021
1	Local AnestheticsIBA 01/2021
1	SuspensionsIBA 01/2021
1	SteroidsIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 12/2020
1	Neurotransmitter Agents (Neurotransmitter)IBA 10/2020
1	Vitamin D FDA LinkGeneric 02/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	AntibodiesIBA 01/2020
1	Anesthetics (Anesthetic Agents)IBA 01/2020
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2020
1	NeuropeptidesIBA 03/2019
1	Biological ProductsIBA 03/2019
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019
1	Progestins (Progestagens)IBA 08/2018

Therapy/Procedure

15	Therapeutics 06/2022 - 01/2011
8	Thrombectomy 08/2022 - 01/2020
7	Secondary Prevention 04/2022 - 09/2014
3	Contraception (Birth Control) 10/2018 - 10/2017
2	Punctures 08/2022 - 01/2020
2	Transcranial Direct Current Stimulation 01/2022 - 11/2021
2	Hormonal Contraception 01/2022 - 10/2018
2	Estrogen Replacement Therapy 01/2021 - 01/2015
2	Nerve Block (Nerve Blocks) 01/2021 - 11/2020
1	Off-Label Use 01/2022
1	Duration of Therapy 01/2022
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2022
1	Injections 01/2021
1	Aftercare (After-Treatment) 09/2020
1	Activities of Daily Living (ADL) 06/2020
1	Gluten-Free Diet 02/2020
1	Thrombolytic Therapy 01/2020
1	Local Anesthesia 01/2020
1	General Anesthesia 01/2020
1	Conscious Sedation 01/2020